Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Related PFE
Top 4 Mid-Cap Stocks In The Oil & Gas Refining & Marketing Industry With The Highest Dividend Yield
Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free